Amgen CFO retiring in 2020
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen declares fourth-quarter dividend
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gets go-ahead on two drugs
Regulators handed Amgen two victories for its drug portfolio, granting the Thousand Oaks biotech giant approval to treat a wider range of patients with osteoporosis and blood disorders. The U.S. Food and Drug Administration approved the use of Amgen’s immune thrombocytopenia drug Nplate for earlier use in adults Oct. 18, allowing it to be given Read More →
Westlake Village BioPartners leads $85 million investment to fight cancer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Tri-county biotech upstarts struggle to maintain stock prices
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.